The FDA has expanded the indication of Emergent BioSolutions' BioThrax anthrax vaccine for use in adults aged 18 to 65 in conjunction with antibiotic treatment, following confirmed or suspected exposure to Bacillus anthracis.
Emergent BioSolutions is plotting to break up its business, keeping its banner work in biodefense under the old name and forming a new company to run with its immuno-oncology candidates.
Emergent BioSolutions just launched a military-grade intramuscular autoinjector device for self-administration of antidotes in the case of a chemical weapons attack.
Emergent BioSolutions has launched a military-grade intramuscular autoinjector device for self-administered antidotes or other chemical threat treatments. For now, the rollout is only ex-U.S., but the infectious disease specialist said it will seek FDA approval for the device, dubbed Emergard.
In a big week for Ebola vaccines, Emergent Biosciences and GlaxoSmithKline have begun a Phase I trial of their candidates, while Bavarian Nordic received €50 million ($56 million) in loans from the European Investment Bank that go in part toward its programs in Ebola and infectious diseases.
In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.
Maryland's Emergent BioSolutions won FDA approval for an injected treatment for anthrax infection, padding the company's stable of biodefense products.
GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
Emergent BioSolutions, already the go-to company for anthrax vaccines, will buy Cangene Corp. for about $222 million, adding to its stable of biodefense contracts and picking up a contract manufacturing business that can kick in some additional revenue.